An in vivo pharmacological evaluation of pardoprunox (SLV308) — A novel combined dopamine D2/D3 receptor partial agonist and 5-HT1A receptor agonist with efficacy in experimental models of Parkinson's disease
Authors:
- L.C. JohnstonLJL.C. Johnston
- A.C. McCrearyAMA.C. McCreary
- 1 August 2010
- journal article
- Published by Elsevier in European Neuropsychopharmacology
- Vol. 20 (8) , 582-593
Abstract
No abstract availableKeywords
This publication has 56 references indexed in Scilit:
- Antipsychotic-Like vs Cataleptogenic Actions in Mice of Novel Antipsychotics Having D2 Antagonist and 5-HT1A Agonist PropertiesNeuropsychopharmacology, 2005
- Treatment of Parkinson's with L-DOPA. The early discovery phase, and a comment on current problemsJournal of Neural Transmission, 2002
- Serotonin 5-HT1A agonist improves motor complications in rodent and primate parkinsonian modelsNeurology, 2001
- Effects of terguride, a partial D2 agonist, on MPTP‐lesioned parkinsonian cynomolgus monkeysAnnals of Neurology, 1993
- Treatment of parkinson's disease with the partial dopamine agonist EMD 49980Movement Disorders, 1993
- Partial dopamine agonist therapy of levodopa‐induced dyskinesiasNeurology, 1992
- Behavioural profile of partial D2 dopamine receptor agonistsPsychopharmacology, 1991
- Dopamine D-2 agonists with high and low efficacies: differentiation by behavioural techniquesJournal of Neural Transmission, 1990
- Therapeutic efficacy of a partial dopamine agonist in drug-free parkinsonian patientsJournal of Neural Transmission, 1985
- A comparison of circling models for the detection of antiparkinson activityPsychopharmacology, 1975